Skip to main content
SpringerLink
Log in

Optimizing the treatment of acute myocardial infarction

  • Editorials
  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.Lancet 1986;1:397–402.

    Google Scholar 

  2. ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET).Lancet 1988;2:525–530.

    Google Scholar 

  3. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial.Lancet 1988;1: 545–549.

    Google Scholar 

  4. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.N Engl J Med 1993;329:673–682.

    Google Scholar 

  5. Cannon CP, McCabe CH, Diver, et al. Comparison of frontloaded tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute MI: Results of the TIMI 4 trial.J Am Coll Cardiol, 1994;24:1602–10.

    Google Scholar 

  6. Simoons ML, Arnold AER. Tailored thrombolytic therapy. A perspectiveCirculation 1993;88:2556–2564.

    Google Scholar 

  7. Gunnar RM, Bourdillon PDV, Dixon DW, et al. ACC/AHA task force report. Guidelines for the early management of patients with acute myocardial infarction.J Am Coll Cardiol 1990;16:249–292.

    Google Scholar 

  8. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.N Engl J Med 1989;320:618–627.

    Google Scholar 

  9. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.N Engl J Med 1993;329:1615.

    Google Scholar 

  10. Simes J, Ross AM, Simoons M, Vander Werf, Topol EJ for the GUSTO investigators. Mortality reduction with accelerated tissue plasminogen activator is explained by early coronary patency (abstract).Circulation 1993;88:I-91.

    Google Scholar 

  11. Dalen JE, Gore JM, Braunwald E, et al. Six- and twelvemonth follow-up of the phase I Thrombolysis In Myocardial Infarction (TIMI) trial.Am J Cardiol 1988;62:179–185.

    Google Scholar 

  12. Lee KL, Sigmon K, George BS, et al. Early and complete reperfusion—a key predictor of survival after thrombolytic therapy (abstract).Circulation 1988;78(Suppl II):2001.

    Google Scholar 

  13. Braunwald E The open-artery theory is alive and well — again.N Engl J Med 1993;329:1650.

    Google Scholar 

  14. Cannon CP, Braunwald E. GUSTO, TIMI and the case for rapid reperfusion.Acta Cardiol 1994;49:l-8.

    Google Scholar 

  15. Lincoff AM, Ellis SG, Galeana A, Sigmon KN, Lee KL, Rosenschein U, for the TAMI Study Group. Is a coronary artery with TIMI grade 2 flow “patent”? Outcome in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial (abstract).Circulation 1992;86(Suppl 1):I-268.

    Google Scholar 

  16. Flygenring BP, Sheehan FH, Kennedy JW, Dodge HT, Braunwald E, for the TIMI Investigators. Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival? (abstract).J Am Coll Cardiol 1991;17(Suppl A):275A.

    Google Scholar 

  17. Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four German multicenter studies.J Am Coll Cardiol 1993;21:1391–1395.

    Google Scholar 

  18. Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?Circulation 1993;87:1792–1805.

    Google Scholar 

  19. Neuhaus KL, Essen RV, Vogt A, et al. for the GRECO Study Group: Dose-ranging study of a novel recombinant plasminogen activator in patients with acute myocardial infarction: Results of the GRECO study (abstract).Circulation 1991;84(Suppl II):II-573.

    Google Scholar 

  20. Cannon CP, McCabe CH, Henry, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 5 trial.J Am Coll Cardiol 1994;23:993–1003.

    Google Scholar 

  21. Lidon R-M, Theroux P, Lesperance J. Apilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.Circulation 1994;89:1567–1572.

    Google Scholar 

  22. Kleiman N, Ohman EM, Califf RM. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after reperfusion therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study.J Am Coll Cardiol 1993;22:381–389.

    Google Scholar 

  23. De Wood MA, Spores J, Notske RN, et al. Medical and surgical management of acute myocardial infarctionAm J Cardiol 1979;44:1356–1364.

    Google Scholar 

  24. Mathey DG, Schofer J, Sheehan FH, et al. Improved survival up to four years after early coronary thrombolysis.Am J Cardiol 1988;61:524–529.

    Google Scholar 

  25. Ellis SG, Ribeiro da Silva E, Heyndricks, et al. Final results of the randomized RESCUE study evaluating PTCA after failed thrombolysis for patients with anterior infarction (abstract).Circulation 1993;88:I-106.

    Google Scholar 

  26. Gibson CM, Cannon CP, Piana RN, et al. Rescue PTCA in the TIMI 4 trial (abstract).J Am Coll Cardiol 1994;225A.

  27. Califf RM, O'Neil W, Stack RS, Topol EJ, et al. for the TAMI group. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis.Ann Intern Med 1988;108:658–662.

    Google Scholar 

  28. Ganz W, Geft I, Shah PK, et al. Intravenous streptokinase in evolving acute myocardial infarction.Am J Cardiol 1984; 53:1209–1216.

    Google Scholar 

  29. Krukoff MW, Green CE, Satler LF, et al. Noninvasive detection of coronary artery patency using continuous ST segment monitoring.Am J Cardiol 1986;57:916–922.

    Google Scholar 

  30. Kurkoff MW, Croll MA, Pope JE, et al. Continuously updated 12-lead ST-segment recovery analysis for myocardial infarction artery patency assessment and its correlation with multiple simultaneous early angiographic observations.Am J Cardiol 1993;71:145-lol.

    Google Scholar 

  31. Anton PM, Gorgels, Vos MA, Letsch IS, et al. Usefulness of the accelerated idioventricular rhythm as a marker for myocardial necrosis and reperfusion during thrombolytic therapy in acute myocardial infarction.Am J Cardiol 1988; 61:231–235.

    Google Scholar 

  32. Goldberg S, Greenspon AJ, Urban PL, et al. Reperfusion arrhythmia: A marker of restoration of antegrade flow during intracoronary thrombolysis for acute-myocardial infarction.Am Heart J 1983;105:26–32.

    Google Scholar 

  33. Norris RM, Brandt PWT, Caughey DE, et al. A new coronary prognostic index.Lancet 1969;1:274–278.

    Google Scholar 

  34. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.Am J Cardiol 1967;20:457–464.

    Google Scholar 

  35. Hands ME, Lloyd BL, Robinson JS, et al. Prognostic significance of electrocardiographic site of infarction after correction for enzymatic size of infarction.Circulation 1986;73: 885–891.

    Google Scholar 

  36. Stone PH, Raabe DS, Jaffe AS, et al, for the MILIS group. Prognostic significance of location and type of myocardial infarction: Independent adverse outcome associated with anterior location.J Am Coll Cardiol 1988;11:453–463.

    Google Scholar 

  37. Hillis LD, Forman S, Braunwald E, and the Thrombolysis In Myocardial Infarction (TIMI) Phase II Co-Investigators. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction.J Am Coll Cardiol 1990; 16:313–315.

    Google Scholar 

  38. Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis In Myocardial Infarction (TIMI) trial, phase II.Circulation 1992;85:1254–1264.

    Google Scholar 

  39. Barbash GI, Hod H, Roth A, et al. Repeat infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia.J Am Coll Cardiol 1990;16:779–783.

    Google Scholar 

  40. Barbash GI, Ohman EM, White HD, Granger C, Califf RM, for the GUSTO Investigators. Rescue thrombolysis in suspected reinfarction following thrombolytic therapy: Experience from the GUSTO trial (abstract).J Am Coll Cardiol 1994;Special Issue, 29A.

Download references

Author information

Authors and Affiliations

  1. CHUS, Service of Cardiology, JIH 5N4, Sherbrooke, Quebec, Canada

    Vincent Dangoisse

Authors
  1. Vincent Dangoisse
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dangoisse, V. Optimizing the treatment of acute myocardial infarction. J Thromb Thrombol 2, 41–44 (1995). https://doi.org/10.1007/BF01063160

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01063160

Search

Navigation